Tysabri and Progressive Multifocal Leukoencephalopathy: Medical Record Checklist (VA)

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

General Health and Science Context

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, weakness, or vision changes, you may be concerned about PML. The medical community has long recognized that certain immunosuppressive therapies carry a risk of opportunistic infections, and Tysabri is associated with a well-documented risk of progressive multifocal leukoencephalopathy. This page outlines the key symptoms, timing of onset, and documentation needed for medical records.

Transition to Occupational Exposure Analysis

Transitioning from this general health perspective to a more specific occupational exposure concern requires a shift in analytical focus. While the general health context considers patient populations and clinical settings, occupational exposure analysis examines the circumstances under which individuals—particularly healthcare workers, pharmaceutical manufacturing personnel, or laboratory staff—may encounter therapeutic agents outside the intended patient use. In the case of Tysabri (natalizumab), a monoclonal antibody used in multiple sclerosis treatment, the question of whether it causes Progressive Multifocal Leukoencephalopathy (PML) extends beyond patient risk to encompass potential exposure pathways in occupational environments. This pivot reframes the inquiry from a purely clinical risk assessment to an evaluation of how workplace contact with the drug or its administration processes might influence PML risk, thereby bridging the gap between general health information and specialized occupational health considerations.

Medical Evidence: Tysabri and PML Causation

Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. The causal relationship between Tysabri and PML is well-established through multiple lines of evidence. Clinical trials documented PML cases in patients receiving Tysabri: two cases occurred among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one case occurred after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases occurred despite the drug's mechanism of action, which involves blocking lymphocyte migration into the central nervous system, thereby reducing immune surveillance against JCV.

Risk Factors and Mechanistic Pathway

Three specific risk factors for PML development in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies indicates prior exposure to the virus, which can reactivate under conditions of reduced immune surveillance. Longer treatment duration increases cumulative exposure to the drug's immunosuppressive effects, while prior immunosuppressant use may further compromise immune function. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocytes from crossing the blood-brain barrier. This reduces normal immune surveillance in the central nervous system, allowing JCV to replicate unchecked in oligodendrocytes, leading to demyelination and the characteristic clinical presentation of PML. Clinical presentation typically includes progressive neurological deficits such as hemiparesis, visual disturbances, cognitive decline, and ataxia, with diagnosis confirmed by MRI findings and detection of JCV DNA in cerebrospinal fluid.

Timeline and Warning Adequacy

The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing data indicate that risk increases with treatment duration, particularly beyond two years. However, cases have been reported earlier, especially in patients with additional risk factors. Adequacy of warnings regarding Tysabri and PML is addressed through multiple regulatory mechanisms. The boxed warning explicitly states that TYSABRI increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also specifies that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and that TYSABRI dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and adhere to specific monitoring requirements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Causation Considerations for Affected Patients

For affected patients, causation-related considerations include the presence of identified risk factors and the temporal relationship between Tysabri exposure and PML diagnosis. The prescribing information advises physicians to consider whether the expected benefit of TYSABRI is sufficient to offset the risk of PML when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This risk-benefit assessment should incorporate individual patient factors, including anti-JCV antibody status, treatment duration, and prior immunosuppressant use. In summary, the evidence demonstrates a clear causal relationship between Tysabri and PML, supported by clinical trial data, identified risk factors, and a plausible mechanistic pathway. The drug's labeling includes comprehensive warnings and a restricted distribution program to mitigate risk, though the infection remains a serious adverse event with high morbidity and mortality.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal relationship between Tysabri and PML?

The causal relationship is well-established through clinical trial data and postmarketing surveillance. Tysabri increases the risk of PML by reducing immune surveillance in the central nervous system, allowing JC virus to replicate. The prescribing information includes a boxed warning stating that TYSABRI increases PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri inhibits alpha-4 integrin, preventing lymphocytes from crossing the blood-brain barrier. This reduces immune surveillance in the CNS, allowing JC virus to replicate in oligodendrocytes, leading to demyelination and PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.